Literature DB >> 24440091

Diabetes complications and adverse health outcomes after coronary revascularization.

Bola F Ekezue1, S B Laditka2, J N Laditka2, J Studnicki2, C M Blanchette2.   

Abstract

AIMS: To examine effects of diabetes complications on health outcomes following coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI), comparing outcomes for patients with diabetes complications to those without diabetes complications.
METHODS: Retrospective analysis of discharge data for 61,566 patients with diabetes age 45 or older who had CABG or PCI in 2007 in United States community hospitals, using data from the Nationwide Inpatient Sample. Analysis included propensity score-adjusted logistic regression.
RESULTS: Of all patients, 21.2% of the weighted sample had diabetes complications. Older patients, Blacks and Hispanics, and those with greater illness severity were more likely to have diabetes complications. Unadjusted rates of in-hospital mortality, postoperative stroke, and renal failure were higher for patients with diabetes complications (rate ratios 2.2, 1.8, and 9.8, respectively; all p<0.0001). In adjusted results, having diabetes complications was associated with higher odds of in-hospital mortality (odds ratio, OR 1.62, 95% confidence interval, CI 1.37-1.91) and renal failure (OR 3.03, CI 1.71-5.39). Compared to CABG, PCI was associated with extra risk of postoperative renal failure for those with diabetes complications.
CONCLUSION: Among patients with diabetes having revascularization, those with diabetes complications have higher risks of in-hospital death and renal failure irrespective of having CABG or PCI. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Administrative data; Coronary by-pass surgery; Diabetes complications; Percutaneous coronary intervention; Propensity score

Mesh:

Year:  2013        PMID: 24440091     DOI: 10.1016/j.diabres.2013.09.019

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  4 in total

1.  Metformin improves the angiogenic potential of human CD34⁺ cells co-incident with downregulating CXCL10 and TIMP1 gene expression and increasing VEGFA under hyperglycemia and hypoxia within a therapeutic window for myocardial infarction.

Authors:  Sherin Bakhashab; Fahad W Ahmed; Hans-Juergen Schulten; Ayat Bashir; Sajjad Karim; Abdulrahman L Al-Malki; Mamdooh A Gari; Adel M Abuzenadah; Adeel G Chaudhary; Mohammed H Alqahtani; Sahira Lary; Farid Ahmed; Jolanta U Weaver
Journal:  Cardiovasc Diabetol       Date:  2016-02-09       Impact factor: 9.951

2.  The Effects of Diabetes Mellitus in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting.

Authors:  Yu Liu; Jinsong Han; Tao Liu; Zhonglu Yang; Hui Jiang; Huishan Wang
Journal:  Biomed Res Int       Date:  2016-09-29       Impact factor: 3.411

3.  Proangiogenic Effect of Metformin in Endothelial Cells Is via Upregulation of VEGFR1/2 and Their Signaling under Hyperglycemia-Hypoxia.

Authors:  Sherin Bakhashab; Farid Ahmed; Hans-Juergen Schulten; Fahad W Ahmed; Michael Glanville; Mohammed H Al-Qahtani; Jolanta U Weaver
Journal:  Int J Mol Sci       Date:  2018-01-19       Impact factor: 5.923

4.  Iminosugars Spiro-Linked with Morpholine-Fused 1,2,3-Triazole: Synthesis, Conformational Analysis, Glycosidase Inhibitory Activity, Antifungal Assay, and Docking Studies.

Authors:  Shrawan R Chavan; Kishor S Gavale; Ayesha Khan; Rakesh Joshi; Navanath Kumbhar; Debamitra Chakravarty; Dilip D Dhavale
Journal:  ACS Omega       Date:  2017-10-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.